Abcuro
Newtonville, Massachusetts, United States · Biotechnology, Health Care, Therapeutics
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients
Key facts
- Headquarters
- Newtonville, Massachusetts, United States
- Employees
- Unknown
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Private
- Website
- abcuro.com
- Company page
Recent activity at Abcuro
- : Abcuro, Inc. raises $66 million in Series D financing led by New Leaf Venture Partners to advance its first-in-class medicine for Inclusion Body Myositis.
- : Abcuro
- : Abcuro Appoints Courtney Cupples as Chief Commercial Officer
- : Abcuro
- : Abcuro, Inc. raised $200 million in a Series C financing led by New Enterprise Associates to advance its first-in-class medicine targeting inclusion body myositis.
- : Abcuro
- : Abcuro Announces $155 Million Oversubscribed Series B Financing To Further Advance Autoimmune Pipeline
- : Abcuro, Inc.
- : Abcuro, Inc.
- : Abcuro, Inc.
Abcuro funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Series D | $66.0M |
| Aug 2026 | Venture | $39.4M |
| Feb 2025 | Venture | $80.0M |
| Feb 2025 | Series C | $200.0M |
| Aug 2023 | Venture | $120.1M |
Leadership
- David Graaf, Executive Officer, Director
- Julius Knowles, Director
- Yajun Xu, Director
- Jason Hafler, Director
- Iyona Rajkomar, Director
- Ryan Berry, Director
- Donald McCarthy, Director
- John Edwards, Director
- Stefano Gulla, Executive Officer, Director
- Julius Knowles, Director
- Yajun Xu, Director
- Daniel Mansuri, Director
Verified email and direct lines for Abcuro’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Abcuro files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Abcuro in the news
- Abcuro's KLRG1 antibody flunks phase 2/3 muscle disease study - Fierce Biotech (Feb 24, 2026)
- A failed drug trial. A cancer diagnosis. How one biotech CEO found a way forward. - The Business Journals (Aug 19, 2026)
- Abcuro Announces Topline Results from the MUSCLE Study of Ulviprubart in Patients with Inclusion Body Myositis - Business Wire (Feb 24, 2026)
- Abcuro Secures $200 Million in Series C Funding to Advance Ulviprubart for Inclusion Body Myositis - Pharmaceutical Executive (Feb 12, 2025)
- Fierce Biotech Fundraising Tracker '26: Nouscom nabs $135M series D; Estuary channels $93M series A - Fierce Biotech (Jan 07, 2026)
- Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis - Business Wire (Feb 12, 2025)
- Newton biotech gets $200M for rare muscle disease drug - The Business Journals (Feb 12, 2025)
- Sanofi-backed Abcuro raises $200M series C to fund pivotal trial of KLRG1 antibody - Fierce Biotech (Feb 12, 2025)
Companies similar to Abcuro
- ZoeNCure Therapeutics Pvt. Ltd · Biotechnology, Health Care, Therapeutics
- Amplifica Holdings Group · Biotechnology, Health Care, Therapeutics
- Oruka Therapeutics · Biotechnology, Health Care, Therapeutics
- NRG Therapeutics · Biotechnology, Health Care, Therapeutics
- AQTUAL · Biotechnology, Health Care, Therapeutics
About Abcuro: questions and answers
What does Abcuro do?
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients
Where is Abcuro headquartered?
Abcuro is headquartered in Newtonville, Massachusetts, United States.
Has Abcuro raised funding?
Yes. Fundz has recorded 5 funding events for Abcuro. The most recent, Series D of $66.0M, was in Aug 2026.
What is the latest news on Abcuro?
On Aug 18, 2026, Abcuro, Inc. raises $66 million in Series D financing led by New Leaf Venture Partners to advance its first-in-class medicine for Inclusion Body Myositis.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy